Last Update 26 Jun 26
Fair value Increased 41%VEXT: Ohio Expansion And Arizona Exit Will Support Future Earnings Potential
Analysts have revised their fair value estimate for Vext Science to CA$0.95 from CA$0.68, reflecting updated assumptions around discount rates, revenue growth, profit margins and the stock's future P/E multiple.
What's in the News for Vext Science
- Vext Science opened its Herbal Wellness Center dispensary in Fairfield, Ohio, now serving both medical and adult-use customers as the company's sixth operating location in the state. The dispensary is supported by its Tier One cultivation and manufacturing facilities in Jackson, Ohio. (Source: Key Developments)
- The Fairfield dispensary, approximately 3,825 square feet and located off Route 4 beside Jungle Jim's International Market in a busy retail area, adds to Vext Science's Ohio retail network, which is capped at eight dispensaries statewide. (Source: Key Developments)
- Vext Science plans to discontinue operations at its Eloy, Arizona cultivation facility and pursue a sale of the asset as part of a broader effort to refine its Arizona footprint and support its focus on Ohio. (Source: Key Developments)
- Management indicated that the Eloy closure follows earlier optimization steps, including the sale of the Prescott Valley facility in November 2023. The Arizona cannabis market has faced oversupply, pricing pressure and statewide cannabis sales that declined approximately 9% year over year in 2025. (Source: Key Developments)
- The company intends to seek approval from the State of Ohio to expand its Jackson cultivation facility to support its vertically integrated footprint and planned openings of additional dispensaries across Ohio within the state's eight-store cap. (Source: Key Developments)
Valuation Changes for Vext Science
- Fair Value Estimate increased from CA$0.68 to CA$0.95, indicating a higher assessed intrinsic value for Vext Science shares based on the revised model inputs.
- Discount Rate adjusted from 0.06% to 6.54%, implying a higher required return in the updated assessment.
- Revenue Growth revised from 20.03% to 15.56%, reflecting more moderate expectations for future $ sales expansion in the model.
- Net Profit Margin updated from 0.03% to 3.67%, indicating a higher assumed level of $ earnings relative to $ revenue in the long run.
- Future P/E raised from 57.24x to 67.91x, pointing to a higher assumed valuation multiple applied to Vext Science earnings in the forecast period.
Catalysts
About Vext Science
Vext Science operates vertically integrated cannabis businesses focused on retail dispensaries and cultivation in Ohio and Arizona.
What are the underlying business or industry changes driving this perspective?
- Rapid scaling of Ohio adult use operations, including the planned build-out to the 8 store license cap and widespread use of drive through formats, is expected to expand high margin retail revenue and lift overall EBITDA as more sales move from wholesale into owned stores.
- Meaningful step ups in cultivation yields, including pilot programs delivering test output nearly 50 percent above current averages, create a path to lower unit costs and structurally higher gross margins as those methods are rolled out across the portfolio.
- Proven ability to remain profitable in a mature, price compressed Arizona market indicates that as weaker operators rationalize capacity, Vext may be positioned to gain share and improve pricing, which could help stabilize revenues and support a recovery in net margins in that state.
- Capital light expansion, combined with operating expenses declining as a percentage of revenue and the major phase of acquisitions and build outs largely completed, may enable the company to convert more of its growth into free cash flow and stronger earnings.
- Growing adult use acceptance in key markets like Ohio, paired with disciplined management of inventory, receivables and tax obligations, could support sustained revenue growth while improving operating cash flow margins as temporary working capital pressures ease.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Vext Science's revenue will grow by 15.6% annually over the next 3 years.
- Analysts assume that profit margins will increase from -29.9% today to 3.7% in 3 years time.
- Analysts expect earnings to reach $2.9 million (and earnings per share of -$0.01) by about June 2029, up from -$15.6 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 68.2x on those 2029 earnings, up from -2.9x today. This future PE is greater than the current PE for the CA Pharmaceuticals industry at 8.7x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.54%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Persistent wholesale price compression and ongoing oversupply in Arizona, which management does not believe has fully bottomed, could structurally cap pricing power and reduce profitability in that mature market. This could drag on consolidated revenue growth and net margins over the long term.
- Regulatory and permitting delays in Ohio, already evident in the Fairfield store being pushed into early 2026 and future openings being tied to uncertain local approvals, may slow the ramp to the 8 store license cap and delay the realization of scale benefits. This could weaken the trajectory of future revenue and earnings.
- Industry wide improvements in cultivation yields, including Vext’s own aggressive yield gains, risk reinforcing oversupply dynamics over time. This could erode unit pricing and limit the benefit of cost efficiencies, compressing gross margins and constraining earnings expansion.
- Volatility in margins driven by IFRS biological asset revaluations, inventory markdowns and fluctuating wholesale prices can obscure underlying performance and may signal an earnings profile that remains lumpy rather than steadily compounding. This could increase uncertainty around future net margins and operating cash flow.
- Reliance on capital light internal funding of expansion, with only $3.7 million of cash on the balance sheet and working capital sensitivity to inventory and tax payments, leaves limited cushion if market conditions deteriorate or if Ohio and Arizona underperform expectations. This could pressure liquidity, constrain growth spending and ultimately weigh on earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of CA$0.95 for Vext Science based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $80.2 million, earnings will come to $2.9 million, and it would be trading on a PE ratio of 68.2x, assuming you use a discount rate of 6.5%.
- Given the current share price of CA$0.26, the analyst price target of CA$0.95 is 72.6% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Vext Science?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
